EFFECT OF INTRAVENOUS ANTI-IL5 (MEPOLIZUMAB) IN HYPEREOSINOPHILIC SYNDROMES

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to assess the safety of anti IL-5 in 18-24 patients with hypereosinophilia (HES) and determine what effect (good or bad) the study medication has on the management of hypereosinophilic syndromes (high number of a particular kind of white blood cell in the blood or in the tissues).¿ 4 groups of 6 individuals will receive Anti IL-5. Groups A and B are safety groups, receiving anti IL-5 with out changes to their current HES medications during infusions. Group C will receive the drug while their current HES medication ( prednisone, etc) would be reduced up to 25% by end of the study. Group D will follow do the same with up to 50% reduction in Current HES medication. Primary outcome measures for this study are safety in this population and reduction of Peripheral blood eosinophil levels and/ or tissue eosinophil level.